WeTrials
Recruiting

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects With HER2 Expressing Advanced Malignant Solid Tumors

What is this study?

This study is testing a new medication called BL-M07D1 to see if it is safe and effective for treating various advanced solid tumors that have a specific protein called HER2. Researchers want to find the right dose and see how well it helps patients when other treatments might not have worked.

Who can participate?

You may be able to join if you are 18 or older, have an advanced cancer with HER2 expression, have a life expectancy of at least 3 months, and agree to follow the study rules. However, you cannot join if you have had recent cancer treatments, major surgery, or certain serious heart conditions.

What will happen?

Participants will receive the study medication, BL-M07D1, while doctors carefully monitor your health and safety. You will have regular check-ins and tests to see how your body and your cancer respond to the treatment.

Where and when?

The study is currently recruiting participants at medical centers in Birmingham, Alabama, and Duarte and Los Angeles, California. More locations may become available over time.

Key Points
  • 1Testing a new medicine called BL-M07D1 for advanced cancers with HER2.
  • 2Open to adults 18 and older who meet specific health and treatment history criteria.
  • 3Currently recruiting patients at select locations in Alabama and California.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Endometrial CancerCervical CancerOvarian CancerUrothelial CarcinomaBiliary Tract CancerBreast CancerLung CancerGastric CancerGastroesophageal-junction CancerEsophageal Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.